<DOC>
	<DOC>NCT01305967</DOC>
	<brief_summary>The purpose of this study is to determine efficacy of SB injection in Non Small Cell Lung Cancer.</brief_summary>
	<brief_title>Investigation of Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description>All eligible patients will receive SB injection therapy for 4 cycles (14~21 days for each cycle). SB injection treatment could be continue after completion of therapy cycles until 6th cycle. It depends on the investigator's decision and patient's will. Efficacy will be evaluated every two cycles.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Age of 1870 years Patients with histologically or cytologically confirmed NonSmall Cell Lung Cancer Patients who had failed more than 1 cycle of standard therapy with advanced or metasatic stage not available to any of resectable surgery or radiotherapy. Patients with measurable lesions Eatern Cooperative Oncolgy Group status 0 to 2. Life expectancy &gt;/= 5 months Patients with adequate organ(heart, kidney, liver)and bone marrow function, as defined by 1. Absolute neutrophil count &gt;/= 1.5 x 10^9/L, Platelet count &gt;/= 100 x 10^9/L 2. Total bilirubin &lt;/= upper limit of normal 3. Aspartate Aminotransferase and/or Alanine Aminotransferase &lt;/= 2 x upeer limit of normal 4. creatinine &lt;/= 1.5 x upeer limit of normal Patients who have signed the informed consent form. Female volunteers admitted to the study must be using a reliable means of contraception Received radiation therapy within 6 weeks before randomization Known brain or spinal cord metastases Have acute infection Have active infection or serious concomitant systemic disorder incompatible with the study Presence or history of malignancy other than NonSmall Cell Lung Cancer Have severe neurologic or psychological disorder Patients who have to receive other chemoradiotherapy or immunotherapy Patients who have received chemotherapy within the previous 30 days Patients who are candidates for combined modality treatment. Patients who have participated in a clinical study within the previous 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>